Humanigen Announces Participation and Presentation at Multiple Conferences in June
Humanigen, Inc. (NASDAQ: HGEN), a biopharmaceutical company, announced participation in various investor conferences in June 2022. Ken Trbovich, SVP Investor Relations, will present at the LD Micro Invitational XII on June 7, 2022. Cameron Durrant, CEO, will present at the Jefferies Global Healthcare Conference on June 10, 2022, and will join a virtual fireside chat at the Lytham Partners Summer 2022 Conference on June 21, 2022. The company focuses on lenzilumab for treating cytokine storm and various inflammatory conditions, continuing its development amidst ongoing clinical trials.
- Participation in multiple investor conferences could enhance visibility and investor interest.
- Ongoing development of lenzilumab for cytokine storm and other inflammatory conditions indicates a strong pipeline.
- Continued clinical trials are subject to regulatory uncertainties and risks that could affect future performance.
LD Micro Invitational XII
Webcast: https://wsw.com/webcast/jeff240/hgen/1826850
The webcast will be available for 90 days under the “Events & Presentations” section of the company’s website at https://ir.humanigen.com/
Webcast: https://wsw.com/webcast/lytham5/hgen/2015304
The webcast will be available for up to 12 months under the “Events & Presentations” section of the company’s website at https://ir.humanigen.com/
About
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005155/en/
Humanigen Investor Relations
trbo@humanigen.com
650-410-3206
Source:
FAQ
What is Humanigen's focus in its business model?
When is Humanigen presenting at the LD Micro Invitational XII?
What conferences will Humanigen participate in during June 2022?
Where can I find more information about Humanigen's presentations?